EUVIMEDEUVIMED entdecken
Übersichtsarbeit

PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations

Aamer Abbas, Jimena Blandon, Jennifer Rude, Ahmed Elfar, Debabrata Mukherjee

Cardiovascular & Hematological Agents in Medicinal Chemistry · 01.04.2012 · 10 (2) · 124-134

DOI: 10.2174/187152512800388948 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular & Hematological Agents in Medicinal Chemistry, erschienen am 01.04.2012. Verfasst von Aamer Abbas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University, El Paso, Texas 79905, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Thiazolidinediones. Die Arbeit wurde bisher 72-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The peroxisome proliferator-activated receptors (PPARs) are nuclear fatty acid receptors, which contain a type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket. These receptors are thought to play an important role in metabolic diseases such as obesity, insulin resistance, and coronary artery disease. Three subtypes of PPAR receptors have been described: PPARα, PPARδ/β, and PPARγ. PPARα is found in the liver, muscle, kidney, and heart. In the liver, its role is to up-regulate genes involved in fatty acid uptake, binding, β-oxidation and electron transport, and oxidative phosphorylation in subcutaneous fat but not in skeletal muscle. PPARδ/β is expressed in many tissues but markedly in brain, adipose tissue, and skin. PPARγ has high expression in fat, low expression in the liver, and very low expression in the muscle. The thiazolidinediones (TZD) are synthetic ligands of PPARγ. By activating a number of genes in tissues, PPARγ increases glucose and lipid uptake, increases glucose oxidation, decreases free fatty acid concentration, and decreases insulin resistance. Although, there is a rationale for the use of TZDs in patients with type 2 diabetes mellitus, clinical studies have produced conflicting data. While currently used TZDs are clearly associated with heart failure (HF) worsening; with regards to cardiovascular outcomes, pioglitazone seems to be related to a trend toward reduction in cardiovascular morbidity and mortality, whereas rosiglitazone may actually increase risk of cardiovascular events. We review the existing literature on TZDs and discuss role and cardiovascular safety of these agents for the contemporary treatment of diabetes. Other side effects of these agents i.e. increase in osteoporosis and possible risk of bladder cancer is also discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsThiazolidinedionesCardiovascular DiseasesDiabetes Mellitus, Type 2HumansInsulin ResistancePPAR gammaRisk

Substanzen

Hypoglycemic AgentsPPAR gammaThiazolidinediones

Autor:innen und Institutionen

  • Department of Internal Medicine, Texas Tech University, El Paso, Texas 79905, USA.

Zitieren

APA

Abbas, A., Blandon, J., Rude, J., Elfar, A., & Mukherjee, D. (2012). PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations. Cardiovascular & Hematological Agents in Medicinal Chemistry, 10(2), 124-134. https://doi.org/10.2174/187152512800388948

Vancouver

Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D. PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2012;10(2):124-134. doi:10.2174/187152512800388948

BibTeX
@article{Abbas2012,
  author = {Abbas, Aamer and Blandon, Jimena and Rude, Jennifer and Elfar, Ahmed and Mukherjee, Debabrata},
  title = {PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations},
  journal = {Cardiovascular & Hematological Agents in Medicinal Chemistry},
  year = {2012},
  volume = {10},
  number = {2},
  pages = {124--134},
  doi = {10.2174/187152512800388948}
}
Kostenlos starten →